Use of CXCL9 as a Biomarker of Acthar Efficacy

• Status: Not yet recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Mallinckrodt
• Treatments: Adrenocorticotropic Hormone

Criteria

Inclusion Criteria:

• Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement

• Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate

Exclusion Criteria:

• Smoking

• Cancer

• Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)

• Inflammatory conditions

• Coexisting lung disease

• Congestive heart failure

• Uncontrolled hypertension

• Recent surgery

• Active peptic ulcers

• Osteoporosis